NasdaqGM:WVEPharmaceuticals
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress
Wave Life Sciences (WVE) drew investor attention after reporting first quarter 2026 results, with sales of US$38.25 million, a net loss of US$26.09 million, and progress across several RNA based clinical programs.
See our latest analysis for Wave Life Sciences.
Despite the earnings beat and clinical updates, the recent 7.17% 1 month share price return to US$7.32 comes after a much steeper 43.43% 3 month share price decline. The 3 year total shareholder return of 83.46% contrasts with a 9.63%...